Drug-Eluting Stents in Coronary Artery Interventions

Drug-eluting stents (DES) have transformed the management of coronary artery disease by combining mechanical scaffolding with local delivery of antiproliferative agents to inhibit neointimal hyperplasia. Since their introduction, DES platforms have evolved through successive generations, incorporating improvements in metal alloys, polymer formulations and strut geometry. Early devices released sirolimus or paclitaxel from durable polymers, markedly reducing restenosis compared to bare-metal stents, but they were associated with delayed endothelialisation and late stent thrombosis. Second-generation DES addressed these concerns through thinner cobalt-chromium or platinum-chromium struts and more biocompatible or biodegradable polymer coatings, yielding superior safety and efficacy. Ongoing innovations include fully bioresorbable scaffolds, polymer-free drug reservoirs and dual-drug systems that balance antirestenotic effects with promotion of vessel healing. Global registries and randomised trials continue to refine optimal stent design, coating composition and post-procedural antiplatelet regimens, ensuring that DES remain the standard of care for percutaneous coronary intervention worldwide.

Research from Nature Portfolio

Recent studies have explored novel biodegradable polymer matrices engineered for sustained release of antiproliferative agents while accelerating endothelial repair. In preclinical models, stents coated with amphiphilic block copolymers have demonstrated extended drug elution profiles with reduced inflammatory cell adhesion. Parallel work on magnesium-based bioresorbable scaffolds has fine-tuned alloy composition and surface microarchitecture to control degradation kinetics, achieving complete scaffold resorption within one year without compromising acute radial strength. A further advance involves dual-agent DES integrating an mTOR inhibitor alongside a vascular endothelial growth factor analogue, which in bench and early clinical evaluation has produced synergistic inhibition of smooth muscle proliferation coupled with enhanced endothelial cell coverage. Together, these advances in polymer science, alloy engineering and combination pharmacotherapy chart a path towards next-generation DES with optimised safety, efficacy and vessel compatibility.

Drug-Eluting Stents in Coronary Artery Interventions publication trend

The graph below shows the total number of articles in drug-eluting stents in coronary artery interventions across all publications each year (not limited to Nature Index journals).

Technical terms

Percutaneous Coronary Intervention (PCI): A minimally invasive procedure in which catheters deliver balloons and stents to open blocked coronary arteries.

Neointimal Hyperplasia: Proliferation of smooth muscle cells and extracellular matrix within the stent, leading to luminal narrowing.

Endothelialisation: Growth of endothelial cells over the stent surface, essential for restoring vessel lining and preventing thrombosis.

Polymer Coating: A drug-loaded film applied to the stent frame that controls the rate and duration of antiproliferative agent release.

Strut Thickness: The cross-sectional dimension of the stent scaffold; thinner struts reduce vessel injury and improve haemodynamics.

References

1. Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials. Cardiovascular Diabetology (2024).
2. Cardiovascular stents: overview, evolution, and next generation. Progress in Biomaterials (2018).
3. Bioresorbable Drug-Eluting Magnesium-Alloy Scaffold for Treatment of Coronary Artery Disease. International Journal of Molecular Sciences (2013).
4. Recent Advances in Manufacturing Innovative Stents. Pharmaceutics (2020).
5. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal (2021).